Nykredit A S Takes $10.99 Million Position in IQVIA Holdings Inc. $IQV

Posted by Brian Himes on Sep 6th, 2026

Nykredit A S purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 56,868 shares of the medical research company’s stock, valued at approximately $10,988,000.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new position in IQVIA in the 2nd quarter valued at approximately $2,811,292,000. Boston Partners purchased a new position in IQVIA in the third quarter valued at $676,698,000. Norges Bank acquired a new position in IQVIA during the 4th quarter worth $497,445,000. Victory Capital Management Inc. increased its holdings in IQVIA by 2,628.1% during the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in IQVIA in the 2nd quarter valued at about $240,911,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $267.34 on Friday. The company has a market capitalization of $44.00 billion, a price-to-earnings ratio of 33.17, a price-to-earnings-growth ratio of 2.29 and a beta of 1.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $271.80. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a 50 day moving average price of $230.54 and a 200 day moving average price of $192.66.

IQVIA (NYSE:IQV – Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the company earned $2.81 earnings per share. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares of the company’s stock, valued at $2,845,883.70. The trade was a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 15,581 shares of company stock valued at $3,796,021 over the last quarter. 1.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on IQV shares. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, August 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research note on Thursday, July 9th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Royal Bank Of Canada boosted their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $243.62.

Check Out Our Latest Report on IQVIA

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.